Nucleoside Metabolic Inhibitor [EPC]

229325 reported adverse events

Drugs of this class: FLUOROURACIL AZACITIDINE DECITABINE CAPECITABINE CLOFARABINE CYTARABINE NELARABINE PENTOSTATIN (DAUNORUBICIN AND CYTARABINE) LIPOSOME CEDAZURIDINE AND DECITABINE GEMCITABINE

These side effects are most commonly reported by patients taking drugs of the Nucleoside Metabolic Inhibitor [EPC] class:

#	Side effect	Count
0	DIARRHOEA	20327
1	DEATH	16682
2	NAUSEA	15080
3	FEBRILE NEUTROPENIA	12487
4	DISEASE PROGRESSION	12298
5	NEUTROPENIA	12166
6	VOMITING	11691
7	FATIGUE	10844
8	PYREXIA	10641
9	OFF LABEL USE	9856

See all common reactions for Nucleoside Metabolic Inhibitor [EPC]

Drugs of the Nucleoside Metabolic Inhibitor [EPC] class are most commonly taken among patients reporting these side effects:

#	Side effect	Count	Frequency
0	DIHYDROPYRIMIDINE DEHYDROGENASE DEFICIENCY	154	0.8701
1	ACUTE MYELOID LEUKAEMIA RECURRENT	634	0.4614
2	PIK3CA-ACTIVATED MUTATION	104	0.4370
3	DIFFUSE LARGE B-CELL LYMPHOMA REFRACTORY	198	0.4323
4	CAECITIS	166	0.3689
5	MYELODYSPLASTIC SYNDROME TRANSFORMATION	178	0.3640
6	PALMAR-PLANTAR ERYTHRODYSAESTHESIA SYNDROME	6551	0.3504
7	DIFFUSE LARGE B-CELL LYMPHOMA RECURRENT	396	0.3356
8	NEUTROPENIC COLITIS	479	0.3340
9	COLORECTAL CANCER METASTATIC	360	0.3203

See all enriched reactions for Nucleoside Metabolic Inhibitor [EPC]